Generic Name and Formulations:
Estradiol acetate 0.9mg, 1.8mg; tabs.
Warner Chilcott Laboratories
Indications for FEMTRACE:
Moderate to severe vasomotor symptoms of menopause.
Start at lowest effective dose. 1 tablet daily.
Breast- or estrogen-dependent cancer. Thromboembolic disorders. Undiagnosed abnormal genital bleeding. Hepatic dysfunction or disease. Pregnancy (Cat.X).
Patients with an intact uterus should always receive a progestin to avoid endometrial hyperplasia. Reevaluate periodically. Conditions aggravated by fluid retention. Hypertriglyceridemia. Do initial complete physical exam and repeat annually (include BP, mammogram, and PAP smear). Discontinue if jaundice occurs. Nursing mothers.
May be affected by CYP3A4 inducers or inhibitors.
See literature. Headache, mastodynia, vaginal bleeding/discharge, GI upset, visual abnormalities; cardiovascular or gallbladder effects, fluid retention, others.
Psychiatry Advisor Articles
- ADHD, Comorbid Bipolar Disorder Share Similar Neurocognitive Profiles
- Anxiety Prevention Interventions: How Effective Are They?
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- No Evidence of Personality Changes Prior to Developing Cognitive Impairment, Dementia
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Physicians Spend Nearly 6 Hours on EHR Tasks Per Day
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder
- Enhanced Vaccination Effectiveness in Older Adults Linked to Positive Mood
- Subjective Cognitive Decline Linked to Alzheimer Biomarker
- Is Hypertension Linked to an Increased Risk of Dementia?
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa